Randomized phase II trial of daily administrations versus alternate-day administrations of S-1 in patients with advanced non-small cell lung cancer
Phase 2
- Conditions
- on-small cell Lung Cancer
- Registration Number
- JPRN-UMIN000006981
- Lead Sponsor
- orth Japan Lung Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)With interstitial pneumonitis or pulmonary fibrosis detectable on chest X-ray 2)Contraindication with S-1 3)With double cancer, multiple cancer 4)With malignant pleural, peritoneal effusion requiring drainage or pericardial effusion 5)With concurrent disease 6)With symptomatic brain metastasis 7)With severe diarrhea 8)Previous treatment with fluoropyrimidines such as S-1, UFT, 5-FU 9) Current use of flucytosine 10)Lactating, pregnant or possibly pregnant women, or those willing to become pregnant 11)Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method